Arcutis Submits Zoryve® (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis
Arcutis向FDA提交Zoryve®(羅氟米特)0.05%乳膏的補充新藥申請,以治療2至5歲患有輕度至中度特應性皮炎的兒童
Arcutis Submits Zoryve® (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis
Arcutis向FDA提交Zoryve®(羅氟米特)0.05%乳膏的補充新藥申請,以治療2至5歲患有輕度至中度特應性皮炎的兒童
譯文內容由第三人軟體翻譯。